Thyroid metastasis of p16-positive OPSCC by Suzuki, Hidenori et al.
CASE REPORT
p16-positive oropharyngeal cancer with rare thyroid metastasis :
A case report
Hidenori Suzuki1, Eiichi Sasaki2, Daisuke Nishikawa3, Daisuke Nishikawa1, Yusuke Koide1, Shintaro Beppu1, 
Hoshino Terada1, and Nobuhiro Hanai1
1Department of Head and Neck Surgery, 2Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan, 
3Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, Kashihara, Japan
Abstract : Thyroid metastasis is rarely diagnosed, and the treatment outcomes in p16-positive oropharyngeal 
squamous cell carcinoma patients with rare thyroid metastasis have not been fully investigated. Here we de-
scribe the case of a patient with p16-positive oropharyngeal squamous cell carcinoma who was diagnosed with 
cT4 N2M1 with rare thyroid metastasis. The patient was a current smoker and was positive for human papil-
lomavirus DNA, with disease progression at 49 days and death at 113 days after completion of cisplatin-based 
concurrent chemoradiotherapy. J. Med. Invest. 67 : 189-191, February, 2020
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INTRODUCTION
 
p16 was established as a surrogate immunohistochemical 
marker of human papillomavirus (HPV) –mediated oropharyn-
geal squamous cell carcinoma (OPSCC) in the eighth edition 
of the American Joint Committee on Cancer Staging Manual 
(1). Previous studies reported that patients with p16-positive 
OPSCC had better survival outcomes than those with p16-nega-
tive OPSCC (2-6). Metastasis of the thyroid gland is rarely diag-
nosed in the clinical practice ; only 46 patients with rare thyroid 
metastasis were found in 18,105 thyroidectomies and 29,708 cy-
tological examination over a 10-years period (9). Moreover, there 
were no mention of thyroid metastasis in a systematic review of 
the end organs of distant metastasis in 220 patients developing 
of HPV-positive OPSCC (3). Therefore, the treatment outcomes 
of p16-positve OPSCC with rare thyroid metastasis remain un-
clear (7). Here we report the survival outcomes of a patient with 
p16-positve OPSCC with rare thyroid metastasis. 
CASE PRESENTATION
A 69-year-old man with a 3-year history of hoarseness and 
dysphagia was referred to our hospital after the previous hos-
pital diagnosed him with pharyngeal squamous cell carcinoma 
based on biopsy. The patient was a 49 pack-year current smoker 
according to a previous report (2). The habit of alcohol consump-
tion was once a week for 40 years. Bilateral neck lymph nodes 
were palpable. Inspection and endoscopy revealed that the pha-
ryngeal tumor had spread to the left tonsil, base of the tongue, 
left pyriform sinus, and lingual surface of the epiglottis ; bilater-
al recurrent nerves palsy was also noted. Enhanced/plane com-
puted tomography (CT) performed from the cervix to the pelvis 
revealed an oropharyngeal tumor at the base of the tongue. The 
tumor had spread to the extrinsic muscle of the tongue, and the 
main lesion had a maximum size of 60 mm, with bilateral neck 
metastasis not larger than 30 mm and heterogeneity of bilateral 
thyroid (Figure 1). The patient was hospitalized for narrow air-
way and dysphagia upon his first visit to our hospital. 
After hospitalization, p16 immunohistochemistry (CINtec 
Histology Kit, clone E6H4, Ventana, Tucson, AZ, USA) of the 
oropharyngeal tumor was performed using an automatic ma-
chine (Ventana BenchMark XT), which indicated that the tumor 
had diffused and was strongly positive. Echo-guided cytology of 
the bilateral thyroid indicated metastatic squamous cell carcino-
ma (Figure 2). Thus, p16-positive OPSCC of cT4N2M1 with rare 
thyroid metastasis was diagnosed based on the 8th edition of the 
American Joint Committee on Cancer Staging Manual (1). 
Cisplatin-based concurrent chemoradiotherapy (CRT) for 
organ preservation definitively underwent after gastrostomy 
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Figure 1.　(A) White light and (B) narrow-band endoscopy images as 
well as (C) axial oropharyngeal, (D) axial thyroid, and (E) coronal thy-
roid enhanced computed tomography images in oropharyngeal cancer.
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and tracheostomy for hypoxemia. A total of 70 Gy with 2 Gy/
daily fraction was performed by intensity-modulated radio-
therapy (RT) following three-dimensional conformal RT to the 
whole neck. Cisplatin (one cycle of 100mg/m2) was administered 
triweekly to the patient ; however, the dosage was reduced to two 
to three cycles of 80 mg/m2 because of febrile neutropenia. The 
first hospitalization period lasted 75 days. 
At 49 days following the completion of CRT, enhanced CT re-
vealed tumor reduction in the RT field as well as multiple distant 
lymph node metastases affecting the mediastinum, hilum, and 
axilla in areas other than the RT field. Additionally, echo-guided 
cytology of the axillary lymph node revealed metastatic squa-
mous cell carcinoma (Figure 3). The patient was diagnosed with 
disease progression due to multiple distant metastases, and the 
best supportive care was selected owing to general fatigue. The 
patient was subsequently re-hospitalized because of dyspnea 
due to pleural effusion and carcinomatous carcinomatosa, and 
eventually died. The re-hospitalization period lasted 7 days. The 
durations from pathological diagnosis and completion of CRT to 
death were 197 days and 113 days, respectively. HPV DNA-pos-
itive was detected in formalin-fixed, paraffin-embedded tumor 
specimen by HPV testing using GP5+/GP6+ PCR, according 
to a previous report (8). HPV 16 was identified based on the L1 
sequence (Figure 4).
DISCUSSION
Rare thyroid metastasis, accounting for 0.13 % of all thyroidec-
tomies (9), has been reported as a case report in various tumors 
such as neuroendocrine tumor from our hospital (10). Thyroid 
metastasis of p16-positve OPSCC is rare and has unknown 
survival outcomes (7). A recent systemic review of 453 articles, 
including 220 cases developing distant metastasis of OPSCC 
with HPV, revealed that the end organs of distant metastasis 
were the lung (160/220), bone (39/220), and non-regional lymph 
nodes (34/220) ; however, no rare thyroid metastasis was report-
ed (3). Moreover, the survival outcomes of two cases with thyroid 
metastasis among 80 cases with recurrent p16-positive OPSCC 
were unclear (4). 
Among patients without distant metastasis, those with 
p16-positive OPSCC had better outcomes than those with 
p16-negative OPSCC (2-4, 6). Moreover, among patients with 
distant metastasis, those with p16-positive OPSCC (28% at 
1-year) had significantly better post-distant metastasis survival 
rate than those with p16-negative OPSCC (13% at 1-year) (5). 
As a clinical predictor in patients with p16-positive OPSCC, 
those with current smoker showed worse outcomes than those 
with never smoking history (2, 6). A large cohort study demon-
strated in 2018 that 48 patients with p16-positive OPSCC who 
were negative for HPV DNA had significantly shorter survival 
outcomes than 340 patients who were positive for HPV DNA and 
had similar survival outcomes as 816 patients with p16-negative 
OPSCC (12). 
Considering the clinical stage and treatment strategy in a 
recent and similar case with a favorable course of p16-positive 
OPSCC with rare thyroid metastasis that did not assess HPV 
DNA and smoking status, no tumor recurrence observed 6 
months after total thyroidectomy following definitive CRT (7). 
In contrast to the previous report (7), our patient presented an 
unfavorable course in terms of disease progression at 49 days 
and death at 113 days following definitive CRT. Because p16 
positivity was a surrogate marker of HPV (11), the present case 
was examined for p16-positive OPSCC with HPV-negative DNA. 
Although the HPV DNA status was not reported in the previous 
case (7), the present case was both p16 and HPV DNA positive. 
Our study suggests the patient’s current smoking status possibly 
led to the unfavorable outcome. We believe that this patient’s 
poor prognosis was strongly affected by his current smoking 
status, which has been independently indicated as a poor predic-
tor for OPSCC in a randomized trial (6). Further accumulation 
Figure 2.　(A) Hematoxylin and eosin staining as well as (B) p16 
immunohistochemical sections for oropharyngeal tumor and (C) right 
and (D) left Papanicolaou staining sections of the thyroid.
Figure 3.　(A) Axial enhanced computed tomography image and (B) 
Papanicolaou staining of the axillary lymph node.
Figure 4.　Polymerase chain reaction gel migration of GP5+/GP6+ 
primers from the oropharyngeal tumor.
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of cases of p16-positive OPSCC with rare thyroid metastasis, 
including smoking status and HPV DNA, is required. Although 
alcohol consumption has been reported to negatively influence 
survival (1), we were unable to suggest the role of alcohol con-
sumption in the development and progression of the cancer in 
this patient.
CONCLUSION
We report that case of a patient with p16-positive OPSCC with 
rare thyroid metastasis and current smoking status who was 
positive for HPV DNA. The patient exhibited disease progres-
sion at 49 days and died 113 days after CRT.
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